Kelonia is developing a next-gen blood cancer treatment that’ll reprogram T-cells to help patients’ immune systems fight cancer.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The exit came just after PIF itself last week released its five-year investment plan for its $925 billion sovereign wealth fund.
Amazon’s Leo has 242 satellites in orbit and plans to start rolling out its service to some customers this year.
High interest rates and prices (an average of $49,275 for new cars in March, per Kelley Blue Book data) have kept buyers from the car market.
The US electrical grid isn’t ready for the double whammy of peak air conditioner usage and peak data center power needs. What happens now?
Madison Air makes climate-control products for both homes and businesses, including brands such as AprilAire and Nortek Data Center Cooling.
If McDonalds struggled to sell $6 cheeseburgers, it’s no wonder Pepsi’s Frito-Lay brand struggled to sell $6 bags of Doritos.
The move comes as OpenAI watches rival Anthropic make big enterprise splashes with its Claude Code and Mythos AI tools.
American Airlines, United, Delta and Southwest represent a whopping 75% share of the US aviation market, according to aviation data firm OAG.
McDonald’s plans to keep prices in its new beverages’ prices lower than competitors like Starbucks and Dutch Bros.
The Strait of Hormuz is supposed to be opening for business under a new ceasefire agreement. So far, that doesn’t seem to be happening.
Spending on newer military tech jumped more than 20% this year, feeding innovation like the device that helped rescuers find a downed aviator.
Americans are playing the most golf in decades, but capitalizing on the trend requires expert-level finesse for equipment-makers.
Delta Airlines and oil giant ExxonMobil say they’re expecting bad news for their financial statements thanks to soaring fuel prices.
n the proposed deal, UMG would merge with Pershing Square SPARC Holdings, a blank-check special-purpose acquisition rights company.
Soleno Therapeutics’s Vykat XR is the first drug to be approved for treating the insatiable hunger caused by Prader-Willi Syndrome.